Crescent Biopharma (CBIO) Interest & Investment Income (2024 - 2026)

Crescent Biopharma (CBIO) has reported Interest & Investment Income for 3 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Interest & Investment Income rose 387.86% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $5.3 million (up 689.66% YoY), while the FY2025 annual figure was $2.9 million, changed N/A from the prior year.
• Interest & Investment Income climbed to $1.5 million in Q2 2026 per CBIO's latest filing, from $1.4 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $1.5 million in Q2 2026 and bottomed at $176000.0 in Q4 2024.
• Historically, Interest & Investment Income has averaged $860428.6 across 3 years, with a median of $1.1 million in 2025.
• On a YoY basis, Interest & Investment Income climbed as much as 669.15% in 2026 and fell as far as 387.86% in 2026.
• Crescent Biopharma's Interest & Investment Income stood at $176000.0 in 2024, then soared by 522.16% to $1.1 million in 2025, then soared by 39.45% to $1.5 million in 2026.
• Business Quant data shows CBIO's Interest & Investment Income at $1.5 million in Q2 2026, $1.4 million in Q1 2026, and $1.1 million in Q4 2025.